IHL Stock Overview
A clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Incannex Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.041 |
| 52 Week High | AU$0.21 |
| 52 Week Low | AU$0.041 |
| Beta | 2.09 |
| 1 Month Change | -34.92% |
| 3 Month Change | -51.76% |
| 1 Year Change | -82.17% |
| 3 Year Change | -71.72% |
| 5 Year Change | 127.78% |
| Change since IPO | -52.87% |
Recent News & Updates
Shareholder Returns
| IHL | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | 1.5% |
| 1Y | -82.2% | 48.7% | 8.7% |
Return vs Industry: IHL underperformed the Australian Pharmaceuticals industry which returned 10.2% over the past year.
Return vs Market: IHL underperformed the Australian Market which returned -0.5% over the past year.
Price Volatility
| IHL volatility | |
|---|---|
| IHL Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IHL's share price has been volatile over the past 3 months.
Volatility Over Time: IHL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Joel Latham | www.incannex.com |
Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Incannex Healthcare Inc. Fundamentals Summary
| IHL fundamental statistics | |
|---|---|
| Market cap | AU$65.07m |
| Earnings (TTM) | -AU$19.98m |
| Revenue (TTM) | AU$1.01m |
64.2x
P/S Ratio-3.3x
P/E RatioIs IHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IHL income statement (TTM) | |
|---|---|
| Revenue | AU$1.01m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.01m |
| Other Expenses | AU$20.99m |
| Earnings | -AU$19.98m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,970.61% |
| Debt/Equity Ratio | 0% |
How did IHL perform over the long term?
See historical performance and comparison